Halaven
(Eribulin Mesylate)Phase 3Small molecule
EisaiEribulin mesylate is used to treat certain types of advanced breast cancer and a rare type of cancer called liposarcoma. It works by stopping cancer cells from dividing and growing.[1] Halaven is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Halaven is one of 133 small molecule programs targeting Breast Carcinoma. It is currently in Phase 3.
7
Indications
70
Total Trials
11
Active Trials
132
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Halaven
EisaiPhase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer37 trials
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Completed·—·Phase 2·NCT03051659·90 enrolled
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04502680·100 enrolled
Show 34 more trials
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Suspended·—·Phase 3·NCT02037529·201 enrolled
Halaven Patient Registry (Metastatic Breast Cancer, MBC)
Unknown status·—··NCT03245112·500 enrolled
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04624711·40 enrolled
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Completed·—·Phase 1·NCT02120469·27 enrolled
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Completed·—·Phase 2·NCT02581839·9 enrolled
Triple-Negative Breast Cancer3 trials
Patients With Advanced Solid Tumors3 trials
23 more indications
Cervical Cancer1 trial
Lymphoma1 trial
Brain Tumors1 trial
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
Completed·—·Phase 1·NCT02338037·8 enrolled
Metastatic1 trial
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Terminated·—·Phase 1·NCT03502681·6 enrolled
Pancreatic Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Fallopian Tube Cancer1 trial
Bladder Cancer1 trial
Recurrent Head and Neck Cancer1 trial
Liposarcoma1 trial
Small Cell Lung Cancer1 trial
Metastatic Solid Tumors1 trial
Metastatic Prostate Cancer1 trial
Salivary Gland Cancer1 trial
Metastatic Bladder Urothelial Carcinoma1 trial
Advanced Urothelial Carcinoma1 trial
Ovarian Carcinosarcoma1 trial
Anatomic Stage III Breast Cancer AJCC v81 trial
Locally Advanced Bladder Urothelial Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eribulin Mesylate. EMBL-EBI & Wellcome Sanger Institute.
- [4]